MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1

BACKGROUND: Ovarian cancer (OC) is the most lethal gynecological malignancy and the second leading cause of cancer-related death in women. Treatment with PARP inhibitors (PARPi), such as Olaparib, has been recently introduced for OC patients, but resistance may occur and underlying mechanisms are st...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Vescarelli, Enrica, Gerini, Giulia, Megiorni, Francesca, Anastasiadou, Eleni, Pontecorvi, Paola, Solito, Luciana, De Vitis, Claudia, Camero, Simona, Marchetti, Claudia, Mancini, Rita, Benedetti Panici, Pierluigi, Dominici, Carlo, Romano, Ferdinando, Angeloni, Antonio, Marchese, Cinzia, Ceccarelli, Simona
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6939329/
https://ncbi.nlm.nih.gov/pubmed/31898520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1490-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados